NYSE: CVRS PRICE: 1.66 -0.03 -1.78% Volume: 481,036 20 minute delay. July 21, 2017

Board of Directors

Jeffrey C. Lightcap , , , Chairman

Jeffrey C. Lightcap was initially elected as a director on August 12, 2014 and was re-elected on April 30, 2015. From March 2008 to August 12, 2014, Mr. Lightcap served as a director of Corindus, Inc., as an appointee of HealthCor, and he served as Chairman from April 12, 2012 to August 12, 2014. Since October 2006, Mr. Lightcap has served as a Senior Managing Director at HealthCor Partners Management, LP, a leading growth equity investor in early and near commercial stage healthcare companies in the diagnostic, therapeutic, medtech and HCIT sectors. From 1997 to mid-2006, Mr. Lightcap was a Senior Managing Director at JLL Partners, a leading middle-market private equity firm. Prior to JLL Partners, Mr. Lightcap was a Managing Director at Merrill Lynch & Co., Inc. in charge of leverage buyout coverage for Merrill Lynch’s mergers and acquisitions group. Prior to joining Merrill Lynch, Mr. Lightcap was a Senior Vice President in the mergers and acquisitions group at Kidder, Peabody & Co. and briefly at Salomon Brothers. Mr. Lightcap currently serves as a director of the following companies: CareView Communications, Inc. (OTCQB: CRVW), a healthcare technology company; IASIS Healthcare Corporation, a privately-held company that owns and operates community-focused hospitals in high growth urban and suburban markets; Practice Partners in HealthCare, a privately-held company specializing in management and operation of ambulatory surgical centers; Paradigm Spine, LLC, a leader in the field of non-fusion, spinal implant technology; and Heartflow, a company focused on the non-invasive diagnosis of coronary artery disease. Mr. Lightcap received a B.E. in Mechanical Engineering from the State University of New York at Stony Brook in 1981 and in 1985 received an M.B.A. from the University of Chicago. We believe Mr. Lightcap’s experience with fundraising in the private equity market and his leadership skills exhibited throughout his career make him well-qualified to serve as one of the Company’s directors.

Mark Toland , , , Director

Mark Toland has been in the medical device space for over 20 years. Prior to joining Corindus as President & CEO, he served as Senior Vice President of Boston Scientific leading BSC's growth and market-innovation initiatives; directly managing corporate sales, marketing, commercial operations, and global solutions. Previously, he led BSC's Interventional Cardiology, Cardiac Rhythm Management, Peripheral Interventions, and Electrophysiology divisions, overseeing over 2000 employees in sales, commercial operations, and customer service. He was accountable for over $4B in revenue and helped lead the integration efforts of key acquisitions, such as Guidant Corporation, Cameron Health (S-ICD), Bridgepoint Medical (CTO), and Watchman (LAAC) that has helped propel the company back to growth. Mark serves on numerous industry boards and has been a faculty member/speaker at numerous medical conferences. He holds a bachelor's degree from the University of Louisville

Jeffrey Gold , , , Director

Jeffrey Gold was initially elected as a director on August 12, 2014 and was re-elected on April 30, 2015. From February 2011 to August 12, 2014, Mr. Gold served as a director of Corindus, Inc. Mr. Gold currently serves as President and Chief Executive Officer for Myoscience, Inc., an innovation-driven medical technology company based in Silicon Valley, California, dedicated to establishing their proprietary platform technology, Focused Cold Therapy™ as the preeminent treatment for conditions involving nerves. He previously served as President and Chief Executive Officer of Velomedix Inc., a venture-backed company that developed a unique technology for rapidly inducing therapeutic hypothermia in patients undergoing severe acute cardiovascular events, such as heart attack and cardiac arrest. Prior to Velomedix, Mr. Gold was a Venture Partner for Longitude Capital where he focused on investments in medical devices. From 2001 to 2005, he was the Chief Executive Officer of CryoVascular Systems, a medical device company developing treatments for peripheral vascular disease. CryoVascular was acquired by Boston Scientific Corporation in 2005. From 1997 to 2000, Mr. Gold was the Chief Operating Officer and Executive Vice President of CardioThoracic Systems (NASDAQ: CTSI), a medical device company focused on developing products to enable off-pump open-heart surgery. CTSI was acquired by Guidant Corporation. Prior to CTSI, Mr. Gold spent 18 years with Cordis Corporation, now the primary cardiovascular device subsidiary of Johnson & Johnson, in a series of roles of increasing responsibility and scope. He was co-founder and President of Cordis Endovascular Systems, the subsidiary company that initially focused on the interventional neuroradiology and peripheral markets. Mr. Gold holds an MBA from the University of Florida and a B.S. in Engineering from Northeastern University and is a graduate of GE’s Manufacturing Management Program. We believe Mr. Gold’s broad experience in a variety of roles managing and investing in medical technology companies make him well qualified to serve as one of the Company’s directors.

Campbell Rodgers M.D. , , MD , , Director

Dr. Rogers has served as Chief Medical Officer of HeartFlow, Inc., a cardiovascular diagnostics company, since March 2012. From July 2006 to March 2012, he served as Chief Scientific Officer and global head of research and development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was associate professor of medicine at Harvard Medical School and the Harvard-M.I.T. division of Health Sciences and Technology and director of the cardiac catheterization and experimental cardiovascular interventional laboratories at Brigham and Women's Hospital. He served as principal investigator for numerous interventional cardiology device, diagnostic and pharmacology trials, is the author of numerous journal articles, chapters and books in the area of coronary artery and other cardiovascular diseases. Dr. Rogers was the recipient of research grant awards from the National Institute of Health and the American Heart Association.  He received his A.B. from Harvard College and his M.D. from Harvard Medical School.  He currently serves as a director of InspireMD, Inc. (NYSE MKT: NSPR), a leader in embolic prevention systems, neurovascular devices and thrombus management technologies, and as a director of CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education and advancement of medical technologies.  Dr. Rogers' qualifications to serve on the board include his significant experience in cardiovascular devices and his familiarity with the operations of medical device companies.

Louis A. Cannon M.D. , , MD , , Director

Dr. Cannon was initially appointed as a director on March 6, 2017 to serve as a Class I director until such time as he stands for election at the Company's 2017 Annual Meeting of Stockholders. Dr. Cannon joined the board in March 2017 in connection with the Company's March 2017 private placement. Dr. Cannon, a past Judah Volkman Scholar in Residence, is triple board certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology. Since March 2012, Dr. Cannon has been a practicing Interventional Cardiologist for the Michigan Heart and Vascular Specialists, the Senior Program Director for the McLaren Northern Michigan Heart and Vascular Institute, and the founder and President of the Cardiac & Vascular Research Center of Northern Michigan, one of the nation's most prominent private research centers. Bringing over two decades of clinical trial experience using cutting edge technologies to treat cardiovascular disease, Dr. Cannon is a recognized leader in cardiovascular research and development. Dr. Cannon graduated from Wright State School of Medicine in Dayton, Ohio in 1984, and completed his Interventional Cardiology fellowship at the University of Cincinnati in 1991. He is the founder and Senior Managing Director of BioStar Private Equity Fund I and BioStar Ventures Fund II and III. Dr. Cannon has served on the strategic advisory boards for Fortune 500 companies including Medtronic, Abbott Laboratories, and The Boston Scientific Corporation. Dr. Cannon has extensive experience in the diagnosis of cardiovascular disease and is a key opinion and thought leader in the medical device cardiovascular space, which we believe makes him well-qualified to serve as a director of the Company.

Nathan R. Harrington , , , Director

Nathan R. Harrington is a new nominee for director of the Company.  Since October 2011, Mr. Harrington has served in various Business Development roles at Philips Healthcare and, in September 2016, was appointed as Head of Business Development for Philips’ Image Guided Therapies business group.  Prior to joining Philips, Mr. Harrington worked for over 8 years at Boston Scientific, a global medical technology leader with a significant focus on cardiovascular solutions, where he held positions in New Business Development for its Cardiac, Rhythm and Vascular Group and in Product Management for its Peripheral Interventions Division.   Prior to Boston Scientific Mr. Harrington spent over 6 years in Management Consulting, with a focus on healthcare and evaluating the commercial potential of emerging medical technology.  Mr. Harrington earned a B.A. from Brown University in 1990 and an MBA from Yale University in 1996.  The Board has concluded that Mr. Harrington's extensive knowledge of the cardiovascular technology space and his experience with the commercialization of both capital and disposable devices makes him well-qualified to serve as a director. 

Email Alerts

Mailing Lists *

Email Address *

Enter the code shown above.

Investor Contact

Scott Madden
508-653-3335 Ext 504